PFKFB3 and graft versus host disease: In this model, inhibition of glycolysis, either by inhibiting mTorc1 (a key molecular regulator of glycolysis) or 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) (a rate limiting step in the glycolytic pathway), reduced the number of alloactivated Th1 cells and ameliorated GVHD (60).